Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07083011 · ClinicalTrials.gov registry record · Phase 2

A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure

A Phase 2 study of Heart Failure With Preserved Ejection Fraction, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 2
Development phase
35
Enrollment target
1
Study location

NCT07083011 is a Phase 2 study of Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 35 participants, below the 2,287-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07083011, a Phase 2 study of Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 2
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)

Conditions Studied

Heart Failure With Preserved Ejection Fraction

Interventions

  • DRUG 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor)

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2025-11
Est. Completion 2027-07
Phase Phase 2

Sponsor

Mayo Clinic

2,844 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07083011

The ClinicalTrials.gov registry entry for NCT07083011 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,287-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (98% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor) is the first listed.

NCT07083011 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT07083011 about?

NCT07083011 is a clinical study titled "A Study of 68Ga-Fibroblast Activation Protein Inhibitor (FAPI) Positron Emission Tomography in Heart Failure". The purpose of this study is to assess the performance of 68Ga- FAPI PET in heart failure with preserved ejection fraction (HFpEF)

What is the current status of trial NCT07083011?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2025-11. Estimated completion is 2027-07.

What conditions does trial NCT07083011 study?

This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction.

What interventions are being tested in trial NCT07083011?

The interventions under investigation include: 68Ga-FAPI (gallium-68-labeled fibroblast activation protein inhibitor) (DRUG).

Who is sponsoring clinical trial NCT07083011?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07083011 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure With Preserved Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure With Preserved Ejection Fraction

All registered trials for this condition

Minnesota

All trials with a study site in Minnesota

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.